Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was recently featured on CNBC's Business Minute. CEO David Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to accelerate the identification of novel drug targets, optimize drug candidates, and streamline development timelines for complex neurological disorders and biodefense applications. The company is actively engaging with pharmaceutical companies and government agencies to advance its biotech and biodefense initiatives. Highlights from the interview can be watched via the following link: https://www.linkedin.com/posts/lunai-bioworks_were-proud-to-share-that-our-client-lunai-activity-7427770187589877760-hp3X

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87836) on February 13, 2026, and is solely responsible for the information contained therein.